Home›Elvitegravir Cobicistat Emtricitabine And Tenofovir Alafenam›Elvitegravir Cobicistat Emtricitabine And Tenofovir Alafenam + Voriconazole

Does Elvitegravir Cobicistat Emtricitabine And Tenofovir Alafenam Interact with Voriconazole?

Elvitegravir Cobicistat Emtricitabine And Tenofovir Alafenam and Voriconazole have a unknown drug interaction according to U.S. FDA drug labeling data. Antifungals: itraconazole ketoconazole voriconazole ↑ elvitegravir ↑ cobicistat ↑ itraconazole ↑ ketoconazole ↑ voriconazole When administering with GENVOYA, the maximum daily dosage of ketoconazole or itraconazole should not exceed 200 mg per day. An assessment of benefit/risk ratio is recommended to justify use of voriconazole with GENVOYA. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Unknown
Elvitegravir Cobicistat Emtricitabine And Tenofovir Alafenam Class
Cytochrome P450 3A Inhibitor
Voriconazole Class
Azole Antifungal
Management
Consult your pharmacist
Data Source
U.S. FDA via OpenFDA

What To Tell Your Doctor or Pharmacist

If you are taking Elvitegravir Cobicistat Emtricitabine And Tenofovir Alafenam and your doctor is considering prescribing Voriconazole (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Never stop or change either medication without first consulting your healthcare provider
💊 Elvitegravir Cobicistat Emtricitabine And Tenofovir Alafenam(Genvoya)+💊 Voriconazole(Vfend)

Severity & Interaction Details

ℹ️
unknown
Interaction documented — severity unclassified
The FDA label notes an interaction but the severity is not classified in our dataset.
Severity scale
MinorContra
On record
Yes
Drug A class
Cytochrome P450 3A Inhibitor
Drug B class
Azole Antifungal
Source
FDA drug label - elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide

What this means in plain English

Antifungals: itraconazole ketoconazole voriconazole ↑ elvitegravir ↑ cobicistat ↑ itraconazole ↑ ketoconazole ↑ voriconazole When administering with GENVOYA, the maximum daily dosage of ketoconazole or itraconazole should not exceed 200 mg per day. An assessment of benefit/risk ratio is recommended to justify use of voriconazole with GENVOYA.

About Elvitegravir Cobicistat Emtricitabine And Tenofovir Alafenam and Voriconazole

Elvitegravir Cobicistat Emtricitabine And Tenofovir Alafenam is a Cytochrome P450 3A Inhibitor, while Voriconazole is an Azole Antifungal. You may recognize them by the brand names Genvoya and Vfend. Both medications are taken by mouth. Elvitegravir Cobicistat Emtricitabine And Tenofovir Alafenam additionally carries an FDA boxed warning, the FDA's strongest safety alert.

Recent research & FDA safety updates

Live

Auto-aggregated from PubMed E-utilities and FDA safety data.

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Elvitegravir Cobicistat Emtricitabine And Tenofovir Alafenam and Voriconazole against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →
Data integrity: Every interaction shown is extracted directly from official U.S. FDA drug labeling via openFDA and the U.S. National Library of Medicine (NIH) — no interactions are invented, inferred, or manually edited. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.